Intestinal Failure

03/01/2017 - "In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a ≥20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. "
01/01/2023 - "This single-center study evaluated the safety and efficacy of teduglutide in pediatric patients with SBS-associated intestinal failure (SBS-IF). "
07/01/2013 - "Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure."
01/01/2020 - "Specialized intestinal failure units have recently reported their outcomes with teduglutide to evaluate if they are consistent with the phase III trials results. "
07/01/2018 - "The available data, albeit limited due to the small number of patients in the so-far performed studies, suggest that teduglutide appears to be safe to use in patients with intestinal failure who are dependent on parenteral support. "

04/01/2012 - "A case demonstrating dramatic improvement in liver function and overall clinical condition in an adult with PNAC and intestinal failure within 8 weeks of changing to a fish oil-based parenteral feed is reported. "
04/01/2010 - "A retrospective review at a tertiary children's hospital (July 2003 to August 2008) identified 6 infants with intestinal failure requiring PN for >6 months who developed severe hepatic dysfunction that was managed by eliminating SLE and providing enteral fish oil. "
01/01/2020 - "Growth in Infants and Children With Intestinal Failure-associated Liver Disease Treated With Intravenous Fish Oil."
01/01/2019 - "Intravenous fish oil (FO) treats pediatric intestinal failure-associated liver disease (IFALD). "
01/01/2018 - "Moreover, the use of fish oil-based ILE, with minimal LA and ALA and abundant DHA and ARA, for treatment of intestinal failure-associated liver disease, does not result in EFAD. "

01/01/2022 - "The results show that the vast majority of US participants use ethanol locks in their population with intestinal failure, with most anticipating or already experiencing reduction in access to ethanol locks. "
05/01/2018 - "Systematic Review and Meta-Analysis of the Utilization of Ethanol Locks in Pediatric Patients With Intestinal Failure."
01/01/2016 - "Ethanol Lock Efficacy and Associated Complications in Children With Intestinal Failure."
04/01/2015 - "A best-practice CCABSI prevention bundle that included ethanol lock prophylaxis in both the hospital and home was successfully implemented, well tolerated, and demonstrated a significant and sustained reduction in preventable harm in the form of CCABSIs in children with intestinal failure."
04/01/2015 - "Twenty-four children with intestinal failure received the ethanol lock prophylaxis CCABSI prevention bundle for a median of 266 days (range, 12-635 days). "

02/01/2016 - "Over the past 2 decades, novel strategies for the management of parenteral lipids have improved morbidity and mortality from PNALD in infants with intestinal failure. "
01/01/2023 - "The objective of this study was to determine the prevalence of EFAD in patients with intestinal failure (IF) who are PN dependent without lipid restriction. "
11/01/2022 - "Given the small daily volumes of these lipids dispensed in infants and children with intestinal failure (IF), the purpose of the study was to identify the optimal storage method. "
10/12/2017 - "A comparison of lipid minimization strategies in children with intestinal failure."
04/01/2016 - "The purpose of this review is to discuss the current state of lipid management in pediatric intestinal failure, especially as it relates to the prevention of PNALD. "

07/01/2014 - "(2) What fat emulsion strategies can be used in pediatric patients with intestinal failure to reduce the risk of or treat PNALD? "
09/01/2018 - "Both are absent/minimal in parenteral nutrition (PN) using soy-oil emulsions ([SO] Intralipid®) traditionally used for neonatal intestinal failure. "
01/01/2013 - "In young children, n-3FA emulsions resulted in improvement in some biochemical outcomes of intestinal failure-associated liver disease but no difference in mortality. "
11/01/2017 - "Use of Mixed-Oil Fat Emulsion to Improve Intestinal Failure-Associated Liver Disease in Long-Term Home Parenteral Nutrition: A Case Report."
10/01/2016 - "While the pathogenesis of intestinal failure-associated liver disease remains unclear, evidence for the contribution of fat emulsions to cholestasis and liver injury has rapidly increased in recent years. "

11/01/2020 - "Oral intake and plasma citrulline predict quality of life in patients with intestinal failure."
10/01/2013 - "Plasma citrulline concentration was determined by chromatography (normal value>15 μmol/L) in 57 patients (age 0.5-18 years) admitted to our Intestinal Rehabilitation Unit with intestinal failure. "
11/01/2011 - "Citrulline concentrations are known to decrease with intestinal failure. "
01/01/2010 - "The aim of the present review is to summarize current knowledge and to define the value of determining plasma citrulline levels for the diagnosis of intestinal failure and, possibly, for monitoring the bowel function."
05/01/2009 - "Plasma citrulline was recently shown to reflect the residual functional enterocyte mass in various situations characterized by intestinal failure. "

01/01/2022 - "The aim of this meta-analysis was to identify and synthesize evidence to assess taurolidine efficacy against comparators for the prevention of CRBSI for people with intestinal failure receiving parenteral nutrition. "
01/01/2022 - "The results show that taurolidine provides effective CRBSI reduction for people with intestinal failure receiving parenteral nutrition."
08/01/2018 - "The aim of this interventional study was to assess the impact of a new strategy using taurolidine-citrate (T-C) prophylactic locks on the CRBSI rate in children with intestinal failure who are receiving HPN. "
01/01/2022 - "Mechanical Complications in Central Lines Using Taurolidine Versus Ethanol Lock Therapy in Children With Intestinal Failure."
07/19/2023 - "This study assessed the incremental costs of 4% tetrasodium ethylenediaminetetraacetic acid (EDTA) compared with taurolidine lock and heparin lock per quality-adjusted life-year (QALY) gained in children with intestinal failure from the healthcare payer and societal perspective. "

12/01/2021 - "In this study, we aim to determine the effect of scheduled antibiotics on gut microbiome in pediatric intestinal failure (IF) and to evaluate the effect of the gut microbiome on nutrition outcomes in IF. "
01/01/2023 - "Adult intestinal failure patients with HPN support and carrying S. aureus were randomly assigned to a 'continuous suppression' (CS) strategy, a repeated chronic topical antibiotic treatment or a 'search and destroy' (SD) strategy, a short and systemic antibiotic treatment. "
12/01/2021 - "Scheduled Empiric Antibiotics May Alter the Gut Microbiome and Nutrition Outcomes in Pediatric Intestinal Failure."
01/01/2022 - "Antibiotic Therapy for Culture-Proven Bacterial Overgrowth in Children With Intestinal Failure Results in Improved Symptoms and Growth."
10/01/2021 - "This study aimed to describe demographic, clinical, and laboratory values in febrile pediatric intestinal failure patients with indwelling central venous catheters presenting to the emergency department to determine if there are low-risk features predictive of negative blood cultures that could help identify a subset that do not need hospitalization and/or broad-spectrum antibiotics. "

06/28/2021 - "Depending on the remaining length of the small intestine, the affected intestinal segment, and the residual bowel function, CIF can result in a wide spectrum of symptoms, from single micronutrient malabsorption to complete intestinal failure. "
01/01/2020 - "When the remaining absorption surface of the intestine cannot absorb enough macronutrients, micronutrients, and water, SBS results in intestinal failure (IF). "
01/01/2020 - "The spectrum of the disease is widely variable from single micronutrient malabsorption to complete intestinal failure, depending on the remaining length of the small intestine, the anatomical portion of intestine and the function of the remnant bowel. "
07/01/2011 - "Children with intestinal failure exhibit a high prevalence of micronutrient deficiencies during intestinal rehabilitation. "
07/01/2011 - "We reviewed medical records of all patients with severe intestinal failure treated from 1999 to 2008 at a multidisciplinary intestinal rehabilitation program who had undergone micronutrient biochemical monitoring. "

12/01/2010 - "Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure."
01/01/2022 - "Glucagon-like peptide-2 (GLP-2) pharmacotherapy is now clinically used to reduce the disease burden of intestinal failure. "
09/01/2012 - "Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure."
01/01/2022 - "Treatment with glucagon-like peptide-2 (GLP-2) analogs improve intestinal adaptation in patients with short bowel syndrome-associated intestinal failure (SBS-IF) and may reduce parenteral support requirements. "
01/01/2020 - "A glucagon-like peptide-2 (GLP-2) analog is used in individuals with intestinal failure who are at risk for liver disease, yet the hepatic actions of GLP-2 are not understood. "

09/01/2011 - "The relationship of recipient preexisting conditions with the risk of postoperative events clearly emphasize the necessity of early referral of patients with intestinal failure to expert transplant program before the onset of life-threatening complications.30 With increased awareness and knowledge regarding referral criteria, transplant criteria, optimal time for transplantation, and medication regiments, improved patient outcomes after intestine and multivisceral transplant will be achieved."
01/01/2018 - "Intestinal transplantation is a successful treatment for children with intestinal failure, but has many potential complications. "
01/01/2018 - "Long-term outcomes in patients with intestinal failure and following intestine transplantation have improved significantly over the last decade. "
09/01/2011 - "Intestinal transplantation in our country is a procedure that can be performed with good outcome and offers a unique therapeutic alternative for a patient with irreversible intestinal failure."
10/15/2008 - "Small bowel transplantation is a successful treatment for irreversible intestinal failure. "

07/01/2014 - "The prognosis of intestinal failure has improved dramatically in the past few decades with the development of parenteral nutrition (PN). "
05/01/2004 - "A team approach to the provision and monitoring of parenteral nutrition in intestinal failure produces the best results."
01/01/2020 - "The ability to deliver nutrients via parenteral nutrition (PN) has markedly improved the prognosis of infants and children with intestinal failure. "
04/01/2016 - "It is very effective for treating intestinal failure, especially for those patients who cannot tolerate parenteral nutrition nor have extensive abdominal disease. "
01/01/2016 - "Long-term outcomes for pediatric patients with intestinal failure have significantly improved with advances in management of parenteral nutrition and the associated comorbidities. "

10/01/2009 - "Optimal timing for referral of children with intestinal failure and improved medical and surgical therapies increase the opportunity for intestinal adaptation without the need for transplant. "
01/01/2022 - "Chronic intestinal failure (CIF) therapy changed significantly in recent decades, and both survival and complication rates improved over time. "
07/01/2007 - "It is a potential marker for evaluating the severity of intestinal failure and the efficacy of rehabilitative therapy in short bowel patients."
07/01/2015 - "The outcome of children with intestinal failure has improved during the past decade following the introduction of novel therapies by dedicated intestinal rehabilitation programs (IRP). "
01/25/2023 - "This is the largest national study to demonstrate improvements in QoL associated with HPS reduction over time using an HPS-specific and patient-centric tool, adding unique data for use of therapies in intestinal failure."

01/01/2017 - "Home parenteral nutrition (HPN) is the mainstay of treatment for patients with Type 3 intestinal failure (IF), however long term data on mortality and nutritional outcomes are limited. "
05/01/1988 - "Home parenteral nutrition is an effective and safe treatment of intestinal failure."
10/01/2019 - "The aim of this study was to evaluate the safety and efficacy of home parenteral nutrition (HPN) service in patients with benign chronic intestinal failure (CIF). "
03/01/2023 - "Home parenteral nutrition (HPN) and/or home parenteral hydration (HPH) are the gold-standard treatment for patients with long-term intestinal failure (IF). "
09/11/2020 - "Home parenteral nutrition in neuroendocrine tumour intestinal failure: improved quality of life and longevity."

07/01/2011 - "The development of total parenteral nutrition (TPN) has dramatically improved the prognosis of patients afflicted with intestinal failure. "
04/26/2020 - "Assessing Non-Invasive Liver Function in Patients with Intestinal Failure Receiving Total Parenteral Nutrition-Results from the Prospective PNLiver Trial."
09/01/2005 - "We believe direct contrast-enhanced MR-venography to be a minimally invasive, panoramic and diagnostically reliable method, which should be considered the first choice in the study of central venous accesses of patients receiving total parenteral nutrition for the medical treatment of intestinal failure. "
01/01/2022 - "Intestinal Failure (IF) is a rare but serious form of organ failure, and patients with IF are dependent on Total Parenteral Nutrition (TPN) to maintain growth and development. "
03/01/2021 - "Some patients with intestinal failure, who are dependent on total parenteral nutrition for long periods, suffer from a lack of suitable conventional venous access points, including axillary, external jugular, internal jugular, subclavian, saphenous, and the brachio-cephalic and femoral veins, due to their occlusion. "